Biosciences
Offspring
Tissue Insights™: The Architecture of Deep Data
Moving Beyond Subjective Scoring to Quantitative Truth
Standard histology gives you a snapshot. Tissue Insights™ provides the entire story. We have integrated three critical pillars - Biobanking, Advanced Assay Technology, and AI Analytics - into a seamless platform designed to answer the most difficult translational questions in drug target validation and antibody development.
It Starts with the Right Tissue
Validated Human Disease Context
The most sophisticated assay in the world is useless if it's run on the wrong sample. We don't just "source" tissue; we curate it. Through our proprietary network and biobank partnerships, we provide access to a vast library of Pathologist-Verified human tissues.
Disease Relevance: Access to specific disease indications (eg. Alzheimer’s, Parkinson’s, Oncology, Chronic Pain).
Quality Control: Every block is reviewed by a board-certified pathologist to confirm tissue quality and diagnosis.
Custom Collections: We build bespoke Tissue Microarrays (TMAs) tailored to your study, allowing you to effectively evaluate your antibodies binding properties across select sets of tissue samples from normal and disease-affected donors in a single run.
Global Reach, Local Compliance: We handle seamless tissue transfer from the US/UK to Sweden, fully GDPR compliant. Through our partnership with Flagship Biosciences, we offer a unified trans-Atlantic workflow.
Visualizing Target Engagement
Multiplex IHC, ISH, and the
Power of isPLA
We specialize in techniques that reveal target expression and activity within the disease affected tissue as well as drug-target engagement.
Multiplex IHC/IF: Why settle for one marker? We visualize multiple biomarkers simultaneously (e.g., target and target activity, cell phenotype, pathology) to analyse the Tissue Microenvironment. It also allow us detect and measure if the drug is penetrating the relevant tissue compartments after in vivo adminitration.
Multiplexed In Situ Hybridization (ISH/RNAscope): When antibodies fail, we visualize target expression at the mRNA and single-cell level with high sensitivity.
Autoradiography: We employ radioligand binding assays for the highly sensitive quantification of target density and drug binding distribution, providing a precise readout of exactly where, and how much, your drug interacts with the target/tissue.
isPLA (In Situ Proximity Ligation Assay):
The Game Changer
-
The Problem: Standard IHC cannot prove protein interaction.
-
The Solution: isPLA generates a signal only when two proteins are within 40nm of each other.
-
The Value: Definitive proof of Drug-Target Engagement, Receptor Dimerization, Measurement of target activity. This is the advanced capability that separates a strategic partner from a standard histology lab.
Turning Pixels into P-Values
AI-Powered Image Analysis
The human eye is subjective. AI is not. We leverage advanced workflows for Digital Pathology with algorithms for deep-learning assisted quantitative image analysis to transform stained tissue sections into robust data sets for strong decisions:
Anatomical Intelligence: We go beyond just counting cells to measure expression within defined tissue compartments and individual cell phenotypes to reveal the true biology of response.
Mechanism Revealed: Beyond simple intensity, we quantify target engagement and biomarker regulation to provide deep insight into your drug's Mechanism of Action (MoA) and disease activity.
Unbiased Decision Data: We generate continuous, quantitative readouts that provide the statistical power and reliability needed for critical Go/No-Go decisions.
_edited.jpg)
The "Tissue Insights™ Advantage
Standard CRO
Generic Human Tissue Sourcing
Standard IHC (Single plex)
Subjective Pathologist Scoring
"We deliver Slides"
Offspring Biosciences
Pathologist-Verified Disease Tissue Banks
Multiplex IF & isPLA (Target detection and engagement)
AI-Driven Quantitative Data
"We deliver Answers"